List of Zmax drug patents
Zmax is owned by Pf Prism Cv.
Zmax contains Azithromycin.
Zmax has a total of 2 drug patents out of which 0 drug patents have expired.
Zmax was authorised for market use on 10 June, 2005.
Zmax is available in for suspension, extended release;oral dosage forms.
Zmax can be used as method of treating bacterial infections.
The generics of Zmax are possible to be released after 14 February, 2024.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6984403 | PF PRISM CV | Azithromycin dosage forms with reduced side effects |
Feb, 2024
(1 year, 6 days from now) | |
| US7887844 | PF PRISM CV | Multiparticulate crystalline drug compositions having controlled release profiles |
Feb, 2024
(1 year, 6 days from now) | |
Drugs and Companies using AZITHROMYCIN ingredient
Market Authorisation Date: 10 June, 2005
Treatment: Method of treating bacterial infections
Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic